Skip to main content

Hycor Extends Deadline on Stratagene Acquisition

NEW YORK, Dec. 30 (GenomeWeb News) - Hycor Biomedical yesterday said it had signed an agreement with privately held Stratagene to extend the deadline for closing its proposed merger with the company until Feb. 27, 2004.

All other terms of the merger agreement, announced in July and originally expected to close in the fourth quarter of 2003, remain the same, according to Hycor.

Hycor said that the extension would permit Stratagene to complete work required to restate its financial statements for the year ended Dec. 31, 2002, and to complete a review of its financial statements for the nine months ended Sept. 30, 2003. The restatement of the S-4 form that Stratagene originally filed in October 2003 "primarily involves accounting for currency transactions in a different manner than Stratagene had previously recognized," according to a Hycor statement.

The financial restatement is expected to result in a moderate improvement to Stratagene's previously reported financial results for the year ended Dec. 31, 2002, Hycor said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.